Treatment for conditions like sepsis striking 500,000 American each year in which half die shows “exciting” results in Phase 3 study
Sunrise Hospital and Medical Center today announced that results have been published by The New England Journal of Medicine (NEJM) concerning a La Jolla Pharmaceutical Company Phase 3 study involving patients at its Las Vegas acute care hospital. The article, entitled “Angiotensin II for the Treatment of Vasodilatory Shock,” is available online and will be in the May 24, 2017 print issue of NEJM. It details the use of the pharmaceutical company’s drug, Angiotensin II, for the Treatment of High-Output Shock during a study in which Sunrise Hospital was the only healthcare facility in Nevada to participate.
The New England Journal of Medicine article can be found here.
Shock is a condition occurring when the blood pressure in a patient is low which disables the body’s ability to get blood or oxygen to organs and tissues. This can cause confusion, an inability to breath, heart arrthymias and it is life threatening. According to researchers, there is a major need for new treatment options for critically ill patients who do not adequately respond to drugs designed to raise blood pressure – called vasopressors. The effect of La Jolla’s proprietary drug, LJPC-501 (angiotensin II) – in combination with other vasopressors – may allow clinicians to leverage all three major means for regulating blood pressure, researchers concluded.
“Sunrise Hospital was fortunate to collaborate with Trauma Surgeon and Critical Care Medicine specialist Dr. Stefan Chock in a study involving highly treatment-resistant patients at Sunrise Hospital,” said Dr. Jeff Murawsky, Chief Medical Officer at Sunrise Hospital and Medical Center. “The results of using a new medication in a research trial to care for shock patients, including patients who have severe sepsis, at Sunrise Hospital were shown to improve blood pressure and established a trend toward better survival rates.”
Dr. Chock, who is an attending physician in Trauma Services at Sunrise Hospital’s busy Emergency Department, added, “Sunrise Hospital was an ideal site for this study because as a tertiary care center, we treat a large number of the sickest patients from Southern Nevada and neighboring regions. The results of the ATHOS-3 study are exciting because it is a big step toward giving clinicians another viable option in treating our most acutely ill patients when all other options have been exhausted.”
About Sunrise Hospital & Medical Center:
As Nevada’s largest acute care facility and Level II Trauma Center, Sunrise Hospital & Medical Center offers high quality, patient-centered healthcare to the residents of Southern Nevada, its surrounding region, and the millions of visitors that come to Las Vegas. The Heart Center at Sunrise offers the most advanced cardiac care and features an Accredited Chest Pain Center. The Nevada Neurosciences Institute – the region’s most comprehensive Joint Commission Certified Primary Stroke Center – provides world-class care for stroke, epilepsy, multiple sclerosis, and other neurological conditions. The Breast Center at Sunrise Hospital is the only NAPBC Accredited Breast Center in Southern Nevada. Located on the same campus is Sunrise Children’s Hospital, Nevada’s largest, most comprehensive children’s hospital. For more information on Sunrise Hospital & Medical Center, visit sunrisehospital.com, follow on Twitter @SunriseLasVegas and facebook.com/SunriseHospital.
Sunrise Hospital & Medical Center
3186 South Maryland Parkway
Las Vegas, Nevada 89109
LJPC‑501 is La Jolla’s proprietary formulation of synthetic human angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin system, serves as one of the body’s central regulators of blood pressure. LJPC‑501 is being developed for the treatment of patients with CRH. LJPC‑501 is the first synthetic human angiotensin II product candidate to be tested in a Phase 3 study.
About Catecholamine Resistant Hypotension
Catecholamine resistant hypotension (CRH) is a life-threatening syndrome in patients with vasodilatory (also known as distributive) shock (dangerously low blood pressure with adequate cardiac function) who cannot achieve target mean arterial pressure (MAP) despite adequate fluid resuscitation and treatment with currently available vasopressors (catecholamines and/or vasopressin). There are approximately 500,000 distributive shock cases in the United States per year, an estimated 200,000 of which develop CRH. More than 50% of CRH patients die within 30 days.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC‑501 is La Jolla’s proprietary formulation of synthetic human angiotensin II for the potential treatment of catecholamine resistant hypotension. LJPC‑401 is La Jolla’s proprietary formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC‑30S is La Jolla’s next-generation gentamicin derivative program that is focused on the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. For more information on La Jolla, please visit www.ljpc.com.